论文部分内容阅读
Alfacell公司对外宣布,在该公司研发的治疗不能切除的恶性间皮细胞瘤(UMM)抗癌药物ranpirnase(ONCONASE)的Ⅲb期临床试验中已经确定有316例死亡病例。为了完成有关ranpirnase新药申请(NDA)最后阶段的工作,该公司根据为该项临床试验设定的统计
Alfacell Inc. announced that 316 deaths have been identified in the Phase IIIb clinical trial developed by the company for the treatment of unresectable malignant mesothelioma (UMM) ranpirnase (ONCONASE®). In order to complete the final phase of the ranpirnase New Drug Application (NDA), the company based its statistics on the clinical trial